2024
Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.
Carmi Levy I, Amitzi L, Lavi E, Zilony - Hanin N, Pode Z, Berger R, Smith K. Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors. Journal Of Clinical Oncology 2024, 42: tps2692-tps2692. DOI: 10.1200/jco.2024.42.16_suppl.tps2692.Peer-Reviewed Original ResearchSolid tumorsIndividualized immunotherapyClinical benefitTumor cellsFirst-in-human phase 1Preliminary evidence of clinical benefitEvidence of clinical benefitImmune-oncology agentsDose-escalation partAdvanced solid tumorsDose-escalation studyRelapsed/refractory solid tumorsAdvanced/metastatic solid tumorsTumor cell lysisPatient tumor cellsPhase 1 studyImmune T cellsAntigen presenting cellsFirst-in-humanStimulate antigen presenting cellsIdentification of biomarkersCTCAE v5Dose expansionIT injectionSystemic therapy
2023
Five Critical Gene-Based Biomarkers With Optimal Performance for Hepatocellular Carcinoma
Liu Y, Zhang H, Xu Y, Liu Y, Al-Adra D, Yeh M, Zhang Z. Five Critical Gene-Based Biomarkers With Optimal Performance for Hepatocellular Carcinoma. Cancer Informatics 2023, 22: 11769351231190477. PMID: 37577174, PMCID: PMC10413891, DOI: 10.1177/11769351231190477.Peer-Reviewed Original ResearchModel gene-gene interactionsCorrecting batch effectsGene-gene interactionsPublished transcriptomic studiesAnalysis of human cancersGene-based biomarkersWhole-transcriptome datasetsGenomic levelTranscriptome dataTranscriptomic studiesBatch effectsEffective therapeutic targetDEGsHuman cancersDisease etiologyMolecular backgroundCaucasian cohortTherapeutic targetIdentified 5Signature patternsIdentification of biomarkersConceptual advancesMiniaturized setting
2022
Functional Connectivity of the Nucleus Accumbens and Changes in Appetite in Patients With Depression
Kroemer NB, Opel N, Teckentrup V, Li M, Grotegerd D, Meinert S, Lemke H, Kircher T, Nenadić I, Krug A, Jansen A, Sommer J, Steinsträter O, Small DM, Dannlowski U, Walter M. Functional Connectivity of the Nucleus Accumbens and Changes in Appetite in Patients With Depression. JAMA Psychiatry 2022, 79: 993-1003. PMID: 36001327, PMCID: PMC9403857, DOI: 10.1001/jamapsychiatry.2022.2464.Peer-Reviewed Original ResearchConceptsMajor depressive disorderNAcc functional connectivityFunctional connectivityBody weightNucleus accumbensTreatment of MDDResting-state functional connectivityCase-control studySymptom-specific associationsHealthy control participantsIdentification of biomarkersClassification of diagnosesCohort studyMost patientsMean ageDepressive episodeDepressive disorderReduced appetiteMagnetic resonance imaging dataMAIN OUTCOMESubstantial burdenDepressive symptomsPatientsVentromedial prefrontal cortexReward circuitAltered gene expression and PTSD symptom dimensions in World Trade Center responders
Marchese S, Cancelmo L, Diab O, Cahn L, Aaronson C, Daskalakis NP, Schaffer J, Horn SR, Johnson JS, Schechter C, Desarnaud F, Bierer LM, Makotkine I, Flory JD, Crane M, Moline JM, Udasin IG, Harrison DJ, Roussos P, Charney DS, Koenen KC, Southwick SM, Yehuda R, Pietrzak RH, Huckins LM, Feder A. Altered gene expression and PTSD symptom dimensions in World Trade Center responders. Molecular Psychiatry 2022, 27: 2225-2246. PMID: 35177824, DOI: 10.1038/s41380-022-01457-2.Peer-Reviewed Original ResearchConceptsPTSD symptom dimensionsPosttraumatic stress disorderCAPS scoresAnxious arousal symptomsSymptom dimensionsWorld Trade Center rescueClinician-Administered PTSD Scale scoresBiomarker of PTSDArousal symptomsCD4 T cellsWorld Trade Center respondersDevelopment of PTSDTotal CAPS scoresCase/control statusTherapeutic target developmentIdentification of biomarkersClinical interview dataResponder cohortPTSD symptom severityPotential biological differencesWTC respondersT cellsGene expressionPTSD studiesPsychiatric disorders
2021
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study
Rouphael N, Maecker H, Montgomery R, Diray-Arce J, Kleinstein S, Altman M, Bosinger S, Eckalbar W, Guan L, Hough C, Krammer F, Langelier C, Levy O, McEnaney K, Peters B, Rahman A, Rajan J, Sigelman S, Steen H, van Bakel H, Ward A, Wilson M, Woodruff P, Zamecnik C, Augustine A, Ozonoff A, Reed E, Becker P, Higuita N, Altman M, Atkinson M, Baden L, Becker P, Bime C, Brakenridge S, Calfee C, Cairns C, Corry D, Davis M, Augustine A, Ehrlich L, Haddad E, Erle D, Fernandez-Sesma A, Hafler D, Hough C, Kheradmand F, Kleinstein S, Kraft M, Levy O, McComsey G, Melamed E, Messer W, Metcalf J, Montgomery R, Nadeau K, Ozonoff A, Peters B, Pulendran B, Reed E, Rouphael N, Sarwal M, Schaenman J, Sekaly R, Shaw A, Simon V. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Science Immunology 2021, 6: eabf3733. PMID: 34376480, PMCID: PMC8713959, DOI: 10.1126/sciimmunol.abf3733.Peer-Reviewed Original ResearchConceptsCOVID-19 cohortProspective longitudinal studyHost immune responseLongitudinal studyCOVID-19Identification of biomarkersHospitalized patientsRespiratory secretionsClinical criteriaDisease progressionImmune responseRadiographic dataImmunologic assaysEffective therapeuticsOptimal timingStudy designBiologic samplingSuch interventionsCohortSeveritySample collectionAssay protocolsPatients
2020
Auditory paired-stimuli responses across the psychosis and bipolar spectrum and their relationship to clinical features
Parker D, Trotti R, McDowell J, Keedy S, Gershon E, Ivleva E, Pearlson G, Keshavan M, Tamminga C, Sweeney J, Clementz B. Auditory paired-stimuli responses across the psychosis and bipolar spectrum and their relationship to clinical features. Biomarkers In Neuropsychiatry 2020, 3: 100014. PMID: 36644018, PMCID: PMC9837793, DOI: 10.1016/j.bionps.2020.100014.Peer-Reviewed Original ResearchSchizoaffective disorderGroup differencesBipolar disorderAuditory paired-stimulus paradigmPaired-stimulus paradigmNeural responsesIdentification of biomarkersB-SNIPClinical featuresSignificant group differencesPsychosis subjectsBipolar-Schizophrenia NetworkPsychosis casesHealthy subjectsPreparatory periodPsychosis syndromeFrequency principal components analysisMania symptomsP50 responsePositive symptomsClinical phenotypeAffective syndromeBipolar spectrumPsychosisPutative biomarkers
2018
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances 2018, 4: eaat7828. PMID: 30214939, PMCID: PMC6135550, DOI: 10.1126/sciadv.aat7828.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell FusionCell Line, TumorCell SurvivalEpithelial CellsFemaleGreen Fluorescent ProteinsHumansHybrid CellsKaryotypingMacrophagesMaleMice, Inbred C57BLMice, TransgenicNeoplastic Cells, CirculatingPancreatic NeoplasmsTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsNeoplastic cellsNumerous neoplastic cellsHuman cancer patientsUrgent medical needPotential therapeutic targetTumor-bearing miceLate-stage progressionHigh lethality rateFuels tumor progressionIdentification of biomarkersOverall survivalDisease stagePeripheral bloodCancer patientsTumor stagingMetastatic spreadNovel biomarkersTherapeutic targetBiologic mechanismsSolid tumorsMedical needMetastatic behaviorTumor progressionCancer highlightLethality rateLipidomics in Carotid Artery Stenosis: Further Understanding of Pathology and Treatment
Zhang W, Zhou X, Guo D, Fu W, Wang L. Lipidomics in Carotid Artery Stenosis: Further Understanding of Pathology and Treatment. Translational Bioinformatics 2018, 14: 55-72. DOI: 10.1007/978-981-13-0620-4_5.Peer-Reviewed Original ResearchCarotid artery stenosisArtery stenosisComprehensive lipid profilingIdentification of biomarkersTherapy of diseasesVascular diseaseStenosisLipidomicsLipid-relatedCarotidHEALTHY studyDiseaseLipid-related diseasesTranslational medicineConfined moleculesPathologyDyslipidemiaTherapyLipid moleculesDiagnosisMoleculesProfiles of samples
2016
Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Williams KA, Swedo SE, Farmer CA, Grantz H, Grant PJ, D’Souza P, Hommer R, Katsovich L, King RA, Leckman JF. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Journal Of The American Academy Of Child & Adolescent Psychiatry 2016, 55: 860-867.e2. PMID: 27663941, DOI: 10.1016/j.jaac.2016.06.017.Peer-Reviewed Original ResearchConceptsPediatric autoimmune neuropsychiatric disordersIntravenous immunoglobulinAutoimmune neuropsychiatric disordersYale-Brown Obsessive Compulsive ScaleChildren's Yale-Brown Obsessive Compulsive ScaleStreptococcal infectionIVIG groupPlacebo groupObsessive-compulsive disorderClinical Global Impression improvement ratingNeuropsychiatric disordersDouble-blind infusionDouble-blind phaseSustained symptom improvementDouble-blind comparisonOpen-label treatmentPrimary outcome measureSevere obsessive-compulsive disorderCY-BOCS total scoreCross-reactive antibodiesIdentification of biomarkersCY-BOCS scoresObsessive Compulsive ScaleImmunomodulatory therapyControlled Trials
2015
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Expert Review Of Hematology 2015, 8: 155-158. PMID: 25697572, DOI: 10.1586/17474086.2015.1016905.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeHigh-risk myelodysplastic syndromeMolecular mutationsRecurrent molecular mutationsReliable clinical predictorsIndependent prognostic valueMyelodysplastic syndrome patientsUrgent clinical needIdentification of biomarkersAgent therapyClinical predictorsPrognostic valuePrognostic subgroupsSyndrome patientsVariable coursePatientsClinical implicationsTET2 mutationsClinical needSyndromeTherapyRecurrent mutationsBiomarkersHMAsResearch priorities
2014
Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.
Isakoff S, He L, Mayer E, Goss P, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Ryan P, Finkelstein D, Hartman A, Garber J, Timms K, Winer E, Ellisen L. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. Journal Of Clinical Oncology 2014, 32: 1020-1020. DOI: 10.1200/jco.2014.32.15_suppl.1020.Peer-Reviewed Original ResearchGlycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acylethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness*
Liu Y, Chen J, Sethi A, Li QK, Chen L, Collins B, Gillet LC, Wollscheid B, Zhang H, Aebersold R. Glycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acylethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness*. Molecular & Cellular Proteomics 2014, 13: 1753-1768. PMID: 24741114, PMCID: PMC4083113, DOI: 10.1074/mcp.m114.038273.Peer-Reviewed Original ResearchConceptsN-acylethanolamine acid amidaseProtein tyrosine kinase 7Non-aggressive prostate cancerTyrosine kinase 7Prostate cancerKinase 7N-glycositesDiverse biological processesPotential tissue biomarkersAggressive prostate cancerPCa tumor tissuesSWATH mass spectrometryTissue microarray analysisProstate cancer tissuesUrgent clinical needIdentification of biomarkersHuman proteomePCa aggressivenessMicroarray analysisBiological processesPCa casesTissue biomarkersTumor aggressivenessNormal prostateCancer tissues
2012
Identification Of Biomarkers To Monitor The Activity Of STX-100, A Humanized Anti-±v²6 Antibody, In A Phase 2a Trial In Idiopathic Pulmonary Fibrosis
Violette S, Sheppard D, Rosas I, Arjomandi M, Rice T, Gilman M, Kaminski N, Prasse A, Maroni B. Identification Of Biomarkers To Monitor The Activity Of STX-100, A Humanized Anti-±v²6 Antibody, In A Phase 2a Trial In Idiopathic Pulmonary Fibrosis. 2012, a2659-a2659. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2659.Peer-Reviewed Original ResearchPhase 2a trialIdiopathic pulmonary fibrosisIdentification of biomarkersPulmonary fibrosisFibrosisTrialsBiomarkersAntibodies
2010
Molecular selection for 'smart' study design in lung cancer
Psyrri A, Burtness B. Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 2010, 7: 621-622. PMID: 20981127, DOI: 10.1038/nrclinonc.2010.156.Peer-Reviewed Original Research
2007
Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer
Campbell AM, Decker RH. Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research 2007, 6: 220-229. PMID: 28529904, PMCID: PMC5420539, DOI: 10.21037/tlcr.2017.03.02.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerAntitumoral responseAdaptive immune systemLung cancerRadiation therapyImmune systemHypofractionated radiation therapyOngoing clinical trialsDose-fractionation schedulesAssessment of efficacyImmunogenicity of antigensIdentification of biomarkersCell deathAntigenic poolCheckpoint inhibitorsCancer vaccinesCytokine administrationClinical trialsImmunological activationFractionation schedulesRadiation-induced cell deathImmunotherapyActivation statusMonoclonal antibodies
2004
Technology Insight: identification of biomarkers with tissue microarray technology
Giltnane JM, Rimm DL. Technology Insight: identification of biomarkers with tissue microarray technology. Nature Reviews Clinical Oncology 2004, 1: 104-111. PMID: 16264828, DOI: 10.1038/ncponc0046.Peer-Reviewed Original ResearchConceptsMicroarray technologyRate of translationGene expression microarraysHigh-throughput technologiesTumor-specific protein expressionHigh-throughput analysisExpression microarraysTarget discoveryTissue microarray technologyMicroarrayProtein expressionPotential targetIdentification of biomarkersTissue microarrayBiomedical researchTargetPowerful toolTranslationExpressionQuality controlRapid mannerDiscovery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply